Teicoplanin Hospira

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status:
European Commission final decision

Overview

On 25 June 2009, the European Medicines Agency (EMEA) completed an arbitration procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Teicoplanin Hospira. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Teicoplanin Hospira do not outweigh its risks, and the marketing authorisation cannot be granted in Germany and in other Member States of the EU (Austria, Ireland, Italy, Portugal, Spain and the United Kingdom).

The company that makes Teicoplanin Hospira, Hospira UK Limited, requested a re-examination of the opinion. After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the recommendation for the refusal of the marketing authorisation on 22 October 2009.

Key facts

Approved name
Teicoplanin Hospira
International non-proprietary name (INN) or common name
teicoplanin
Reference number
EMEA/H/A-29/1084
Type
Article 29(4) referrals

This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.

Status
European Commission final decision
Opinion date
22/10/2009
EC decision date
29/01/2010

All documents

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

  • Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes havebeen recommended by the Committee
  • Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be takenfor the marketing authorisation(s) such as safety measures or extra studies

How useful was this page?

Add your rating